Sitaxentan    (DrugBank: Sitaxentan)

1 disease
IDDisease name (Link within this page)Number of trials
86Pulmonary arterial hypertension9

86. Pulmonary arterial hypertension    [ 1,083 clinical trials,   667 drugs,   (DrugBank: 122 drugs),   98 drug target genes,   185 drug target pathways]
Searched query = "Pulmonary arterial hypertension", "PAH", "IPAH", "HPAH", "Eisenmenger syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
9 / 1,083 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01251848
(ClinicalTrials.gov)
January 20111/12/2010Drug Interaction Between Ritonavir And SitaxsentanA Phase 1, Open Label, Randomized, Multiple Dose Study To Assess The Two-Way Drug Interaction Between Sitaxsentan And Low Dose Ritonavir In Healthy SubjectsPulmonary Arterial HypertensionDrug: Sitaxentan;Drug: Ritonavir;Drug: SitaxsentanPfizerNULLWithdrawn21 Years55 YearsBoth0Phase 1NULL
2JPRN-JapicCTI-101370
10/12/201009/12/2010Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension PatientsA Phase 3, Multi-Center, Open Label Study To Evaluate The Long-Term Safety Of Sitaxentan Sodium In Japanese Subjects With Pulmonary Arterial Hypertension Pulmonary Arterial HypertensionIntervention name : Sitaxentan sodium
INN of the intervention : Sitaxentan
Dosage And administration of the intervention : 100 mg, once daily
Control intervention name : null
Pfizer Japan Inc.NULL1680BOTH35Phase 3NULL
3NCT01244620
(ClinicalTrials.gov)
November 201015/11/2010A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple DosesA Phase 1, Open Label, Randomized, Four Period, Crossover, Multiple Dose Study To Assess The Pharmacokinetic Interaction Between Sitaxsentan and Tadalafil and The Effect Of Sildenafil On Sitaxsentan PK In Healthy SubjectsPulmonary Arterial HypertensionDrug: sitaxentan;Drug: tadalafil;Drug: sitaxsentan;Drug: sildenafilPfizerNULLTerminated21 Years55 YearsAll16Phase 1Singapore
4NCT01210443
(ClinicalTrials.gov)
November 201011/8/2010Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension PatientsA Phase 3, Multi-Center, Open Label Study To Evaluate The Long-Term Safety Of Sitaxentan Sodium In Japanese Subjects With Pulmonary Arterial HypertensionHypertension, PulmonaryDrug: SitaxentanPfizerNULLTerminated16 Years80 YearsAll2Phase 3Japan
5JPRN-JapicCTI-101369
20/8/201009/12/2010A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension PatientsA Phase 3, Multi-Center, Open Label Study to Investigate Safety and efficacy of Sitaxentan THERAPY in japanese Subjects with Pulmonary Arterial Hypertension Pulmonary Arterial HypertensionIntervention name : Sitaxentan sodium
INN of the intervention : Sitaxentan
Dosage And administration of the intervention : 100 mg, once daily
Control intervention name : null
Pfizer Japan Inc.NULL1680BOTH35Phase 3NULL
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01204853
(ClinicalTrials.gov)
August 20106/8/2010A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension PatientsA Phase 3, Multi-Center, Open Label Study To Evaluate The Safety And Efficacy Of Sitaxentan Sodium In Japanese Subjects With Pulmonary Arterial HypertensionHypertension, PulmonaryDrug: SitaxentanPfizerNULLTerminated16 Years80 YearsAll2Phase 3Japan
7NCT00995566
(ClinicalTrials.gov)
April 201017/9/2009A Non-Interventional, Patient Registry For The Collection Of Pre-Defined Safety Data In Patients Prescribed ThelinThelin (Sitaxentan Sodium) Patient Safety Registry A Non-Interventional, Patient Registry For The Collection Of Pre-Defined Safety Data In Patients Prescribed ThelinPulmonary Arterial HypertensionDrug: Sitaxentan sodiumPfizerNULLTerminated18 YearsN/AAll54N/ABelgium;France;Germany;Sweden
8NCT01445873
(ClinicalTrials.gov)
December 1, 200930/9/2011Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH)NON-INTERVENTIONAL (NI) DRUG STUDY PROTOCOL: THREE-COUNTRY PILOT STUDY FOR RETROSPECTIVE CHART REVIEW OF EFFECTIVENESS OF THELIN® (SITAXSENTAN) IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH)Pulmonary Arterial HypertensionDrug: Sitaxentan sodiumPfizerNULLCompleted18 YearsN/AAll36NULL
9NCT00080457
(ClinicalTrials.gov)
May 20031/4/2004Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial HypertensionA Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Sitaxsentan Sodium (Thelin™) Treatment With an Open-Label Bosentan Arm in Patients With Pulmonary Arterial Hypertension (PAH)Pulmonary HypertensionDrug: sitaxsentan sodiumEncysive PharmaceuticalsNULLCompleted12 Years75 YearsBoth240Phase 3United States